Skip to main
University-wide Navigation

The project aims to: 1) analyze gabapentin prescribing in Kentucky since July 1, 2017, when gabapentin became a Schedule V controlled substance; 2) evaluate the effect of Kentucky’s 2017 SB32, which amended KRS 218A.202 to require the Administrative Office of the Courts to forward drug conviction data to the Kentucky Cabinet for Health and Family Services for inclusion in KASPER (Kentucky All Schedule Prescription Electronic Reporting); and 3) develop continuing education for use of drug conviction data in clinical context.

Program Contact

Program Contact
Photo Contact Information
Svetla Slavova photo
Svetla Slavova
Associate Professor/ KIPRC Faculty Associate

Latest News & Resources for This Program

KIPRC presents research at 2022 Rx Summit